Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.
作者信息
Gan Sushrima, Dawed Adem Y, Donnelly Louise A, Nair Anand T N, Palmer Colin N A, Mohan Viswanathan, Pearson Ewan R
机构信息
University of Dundee, Dundee, U.K.
Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai, India.
出版信息
Diabetes Care. 2020 Dec;43(12):e202-e203. doi: 10.2337/dci20-0049.
Abstract
摘要
相似文献
1
Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.对关于Gan等人的评论的回应。现代糖尿病治疗药物二肽基肽酶-4抑制剂（DPP-4i）、钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）和胰高血糖素样肽-1受体激动剂（GLP-1RA）在白人和亚洲糖尿病患者中的疗效：一项随机对照试验的系统评价和荟萃分析。《糖尿病护理》2020年；43:1948 - 1957。
Diabetes Care. 2020 Dec;43(12):e202-e203. doi: 10.2337/dci20-0049.
2
Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.对甘等人的评论。现代糖尿病治疗药物二肽基肽酶-4抑制剂（DPP-4i）、钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）和胰高血糖素样肽-1受体激动剂（GLP-1RA）在白种人和亚洲糖尿病患者中的疗效：一项随机对照试验的系统评价和荟萃分析。《糖尿病护理》2020年；43:1948 - 1957。
Diabetes Care. 2020 Dec;43(12):e200-e201. doi: 10.2337/dc20-1950.
3
Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.现代糖尿病治疗药物 DPP-4i、SGLT-2i 和 GLP-1RA 在白种人和亚洲糖尿病患者中的疗效：一项随机对照试验的系统评价和荟萃分析。
Diabetes Care. 2020 Aug;43(8):1948-1957. doi: 10.2337/dc19-2419.
4
The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.注射用胰高血糖素样肽-1（GLP-1）受体激动剂与口服二肽基肽酶-4（DPP-4）抑制剂和钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂的安慰剂反应：一项系统评价和荟萃分析。
Br J Clin Pharmacol. 2016 Jul;82(1):301-14. doi: 10.1111/bcp.12925. Epub 2016 Apr 22.
5
Should Baseline Hemoglobin A or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review.基线血红蛋白 A1c 或 SGLT-2i 剂量是否指导 2 型糖尿病患者使用 SGLT-2i 与 DPP-4i 治疗？一项荟萃分析和系统评价。
J Clin Pharmacol. 2020 Aug;60(8):980-991. doi: 10.1002/jcph.1599. Epub 2020 May 12.
6
Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.钠-葡萄糖共转运蛋白 2 抑制剂与 2 型糖尿病患者心力衰竭风险降低的相关性：一项真实世界的全国范围内基于人群的队列研究。
Cardiovasc Diabetol. 2018 Jun 23;17(1):91. doi: 10.1186/s12933-018-0737-5.
7
Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.2 型糖尿病与心力衰竭风险：来自心血管结局试验的系统评价和荟萃分析。
Endocrine. 2019 Jul;65(1):15-24. doi: 10.1007/s12020-019-01931-y. Epub 2019 Apr 26.
8
Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.比较 SGLT-2 抑制剂与 DPP-4 抑制剂作为 2 型糖尿病患者二甲双胍的附加治疗：系统评价和荟萃分析。
Diabetes Metab. 2018 Mar;44(2):112-120. doi: 10.1016/j.diabet.2018.01.017. Epub 2018 Feb 7.
9
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂与老年 2 型糖尿病患者骨折风险的关联。
JAMA Netw Open. 2021 Oct 1;4(10):e2130762. doi: 10.1001/jamanetworkopen.2021.30762.
10
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.新型降糖药物与二甲双胍联合治疗 2 型糖尿病的心血管疗效的性别差异。
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. doi: 10.1161/JAHA.119.012940. Epub 2020 Jan 4.
本文引用的文献
1
Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.现代糖尿病治疗药物 DPP-4i、SGLT-2i 和 GLP-1RA 在白种人和亚洲糖尿病患者中的疗效：一项随机对照试验的系统评价和荟萃分析。
Diabetes Care. 2020 Aug;43(8):1948-1957. doi: 10.2337/dc19-2419.
2
Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.对甘等人的评论。现代糖尿病治疗药物二肽基肽酶-4抑制剂（DPP-4i）、钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）和胰高血糖素样肽-1受体激动剂（GLP-1RA）在白种人和亚洲糖尿病患者中的疗效：一项随机对照试验的系统评价和荟萃分析。《糖尿病护理》2020年；43:1948 - 1957。
Diabetes Care. 2020 Dec;43(12):e200-e201. doi: 10.2337/dc20-1950.
3
Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.2型糖尿病亚洲患者使用钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂的心血管结局：心血管结局试验的系统评价和荟萃分析
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):715-722. doi: 10.1016/j.dsx.2020.04.051. Epub 2020 May 15.
4
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2019 年更新版：《2018 年美国糖尿病协会（ADA）与欧洲糖尿病研究协会（EASD）关于 2 型糖尿病患者高血糖管理的共识报告》。
Diabetes Care. 2020 Feb;43(2):487-493. doi: 10.2337/dci19-0066. Epub 2019 Dec 19.
5
No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.亚洲和非亚洲 2 型糖尿病患者使用钠-葡萄糖共转运蛋白 2 抑制剂治疗的疗效和全因死亡率无差异：一项荟萃分析。
J Diabetes Investig. 2018 Jul;9(4):850-861. doi: 10.1111/jdi.12760. Epub 2017 Nov 13.
Zotero 插件